<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263717</url>
  </required_header>
  <id_info>
    <org_study_id>2007p-000638</org_study_id>
    <nct_id>NCT01263717</nct_id>
  </id_info>
  <brief_title>Effects of Growth Hormone Releasing Hormone in HIV</brief_title>
  <official_title>Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV-infection and its treatment are often associated with an increase in belly fat, as well
      as abnormal cholesterol and problems metabolizing sugar. People with HIV infection and
      increased belly fat often have decreased growth hormone (GH) levels. Low GH levels may
      contribute independently to increased belly fat and to increased cardiovascular risk through
      effects on sugar metabolism, inflammation, and other mechanisms. Tesamorelin, a growth
      hormone releasing hormone (GHRH) analogue, has been shown to to reduce belly fat in patients
      with HIV-associated abdominal fat accumulation. However, the effects of tesamorelin on fat
      accumulation in the liver and muscle, sugar metabolism, and cardiovascular health are not yet
      known. The current study is designed to determine the effects of tesamorelin treatment on fat
      accumulation in the muscle and liver, insulin sensitivity and sugar metabolism, and markers
      of cardiovascular health including blood vessel thickness (carotid intima media thickness
      [cIMT]) and markers of inflammation in the body. The investigators hypothesize that
      tesamorelin will decrease fat accumulation in the liver and muscle and will decrease markers
      of inflammation, with either neutral or beneficial effects on glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Fat</measure>
    <time_frame>6 months</time_frame>
    <description>Hepatic fat as measured by magnetic resonance (MR) spectroscopy, and expressed by normalizing lipid to water and expressing as a percent (lipid-to-water percent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral Adipose Tissue</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visceral adipose tissue area as measured by single-slice computed tomography (CT) scan at the L4 vertebra.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intramyocellular Lipid</measure>
    <time_frame>6 months</time_frame>
    <description>Intramyocellular lipid (IMCL) as measured by magnetic resonance (MR) spectroscopy of the calf. Soleus IMCL normalized to creatinine (IMCL/Cr based on areas determined by spectroscopy) was measured. The change over 6 months is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous Growth Hormone Secretion</measure>
    <time_frame>6 months</time_frame>
    <description>Endogenous growth hormone (GH) concentrations measured by overnight frequent blood sampling every 20 minutes. Mean overnight GH concentration is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>In a subgroup of 1/2 of the subjects, euglycemic hyperinsulinemic clamp will be performed to assess insulin-stimulated glucose uptake. Insulin stimulated glucose uptake (M) calculated using the method of DeFronzo is shown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Hemoglobin A1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Like Growth Factor 1 (IGF-I)</measure>
    <time_frame>6 months</time_frame>
    <description>Insulin Like Growth Factor 1 (IGF-I).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting lipids. Triglyceride value is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intimal Medial Thickness (cIMT)</measure>
    <time_frame>6 months</time_frame>
    <description>Carotid Intimal Medial Thickness (cIMT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tolerance</measure>
    <time_frame>6 months</time_frame>
    <description>Glucose tolerance as measured by standard oral glucose tolerance test. 2-hour glucose is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>6 months</time_frame>
    <description>adiponectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic Markers</measure>
    <time_frame>6 months</time_frame>
    <description>Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) measured in serum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>HIV</condition>
  <condition>HIV Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Tesamorelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (inactive injection)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tesamorelin</intervention_name>
    <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
    <arm_group_label>Tesamorelin</arm_group_label>
    <other_name>Egrifta, growth hormone releasing hormone, TH9507</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection</description>
    <arm_group_label>Placebo (inactive injection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women age 18-65

          2. Previously diagnosed HIV infection

          3. Stable antiviral regimen for at least 12 weeks prior to enrollment

          4. WC&gt;95 cm and WHR&gt;0.94 for male, WC&gt;94 cm and WHR&gt;0.88 for female occurring in the
             context of treatment for HIV disease

          5. Subjective evidence of at least one of the following recent changes, occurring during
             the treatment of HIV disease: increased abdominal girth, relative loss of fat in the
             extremities, or relative loss of fat in the face

          6. For female subjects 40yo or older, negative mammogram within one year of baseline

        Exclusion Criteria:

          1. Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months
             of the study. Stable use of testosterone (&gt; 6 mos) at dose equivalent to 200 mg IM q 2
             weeks or &lt; 10g/day to skin will be permitted.

          2. Use of GH or GHRH within the past 6 months

          3. Change in lipid lowering or antihypertensive regimen within 3 months of screening

          4. Fasting blood sugar &gt; 126 mg/dL, SGOT &gt; 2.5 times ULN, HgB &lt; 12.0 g/dL, creatinine &gt;
             1.4 mg/dL, CD4 count &lt; 200

          5. Severe chronic illness or active malignancy or history of pituitary malignancy or
             history of colon cancer

          6. For men, history of prostate cancer or evidence of prostate malignancy by PSA &gt; 5
             ng/mL

          7. Prior history of hypopituitarism, head irradiation or any other condition known to
             affect the GH axis

          8. For women, positive urine hCG

          9. Oral contraceptives, depo provera or combined progesterone-estrogen injections,
             transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months
             of the study.

         10. Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral
             aneurysm clip.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.</citation>
    <PMID>25038357</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <results_first_submitted>September 8, 2014</results_first_submitted>
  <results_first_submitted_qc>October 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2014</results_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>lipodystrophy</keyword>
  <keyword>tesamorelin</keyword>
  <keyword>Egrifta</keyword>
  <keyword>growth hormone releasing hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tesamorelin</title>
          <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Inactive Injection)</title>
          <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline Visit</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tesamorelin</title>
          <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Inactive Injection)</title>
          <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="46" upper_limit="54"/>
                    <measurement group_id="B2" value="53" lower_limit="49" upper_limit="58"/>
                    <measurement group_id="B3" value="51.5" lower_limit="46" upper_limit="56.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Fat</title>
        <description>Hepatic fat as measured by magnetic resonance (MR) spectroscopy, and expressed by normalizing lipid to water and expressing as a percent (lipid-to-water percent).</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for some subjects. Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Fat</title>
          <description>Hepatic fat as measured by magnetic resonance (MR) spectroscopy, and expressed by normalizing lipid to water and expressing as a percent (lipid-to-water percent).</description>
          <population>All available data were used; data were not available for some subjects. Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
          <units>Change in hepatic lipid-to-water %</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-6.4" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-0.6" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visceral Adipose Tissue</title>
        <description>Change in visceral adipose tissue area as measured by single-slice computed tomography (CT) scan at the L4 vertebra.</description>
        <time_frame>6 months</time_frame>
        <population>Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Visceral Adipose Tissue</title>
          <description>Change in visceral adipose tissue area as measured by single-slice computed tomography (CT) scan at the L4 vertebra.</description>
          <population>Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
          <units>change in cm^2 after 6 months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" lower_limit="-53" upper_limit="-15"/>
                    <measurement group_id="O2" value="8" lower_limit="-14" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intramyocellular Lipid</title>
        <description>Intramyocellular lipid (IMCL) as measured by magnetic resonance (MR) spectroscopy of the calf. Soleus IMCL normalized to creatinine (IMCL/Cr based on areas determined by spectroscopy) was measured. The change over 6 months is reported.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for some subjects. Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Intramyocellular Lipid</title>
          <description>Intramyocellular lipid (IMCL) as measured by magnetic resonance (MR) spectroscopy of the calf. Soleus IMCL normalized to creatinine (IMCL/Cr based on areas determined by spectroscopy) was measured. The change over 6 months is reported.</description>
          <population>All available data were used; data were not available for some subjects. Data from 1 patient who was discontinued between the 3 and 6mo visits for adverse event are included. These data were obtained at a termination visit.</population>
          <units>Change in ratio of IMCL/Cr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-3.9" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-5.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endogenous Growth Hormone Secretion</title>
        <description>Endogenous growth hormone (GH) concentrations measured by overnight frequent blood sampling every 20 minutes. Mean overnight GH concentration is given.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for some subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Endogenous Growth Hormone Secretion</title>
          <description>Endogenous growth hormone (GH) concentrations measured by overnight frequent blood sampling every 20 minutes. Mean overnight GH concentration is given.</description>
          <population>All available data were used; data were not available for some subjects.</population>
          <units>Change in ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.15" upper_limit="0.57"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.07" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>In a subgroup of 1/2 of the subjects, euglycemic hyperinsulinemic clamp will be performed to assess insulin-stimulated glucose uptake. Insulin stimulated glucose uptake (M) calculated using the method of DeFronzo is shown.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for some subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>In a subgroup of 1/2 of the subjects, euglycemic hyperinsulinemic clamp will be performed to assess insulin-stimulated glucose uptake. Insulin stimulated glucose uptake (M) calculated using the method of DeFronzo is shown.</description>
          <population>All available data were used; data were not available for some subjects.</population>
          <units>Change in mg/kg/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.2" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.6" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <description>Hemoglobin A1c.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for one subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>Hemoglobin A1c.</description>
          <population>All available data were used; data were not available for one subject.</population>
          <units>Change in %</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.04" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.07" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Like Growth Factor 1 (IGF-I)</title>
        <description>Insulin Like Growth Factor 1 (IGF-I).</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for one subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Like Growth Factor 1 (IGF-I)</title>
          <description>Insulin Like Growth Factor 1 (IGF-I).</description>
          <population>All available data were used; data were not available for one subject.</population>
          <units>Change in ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="92"/>
                    <measurement group_id="O2" value="7" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Panel</title>
        <description>Fasting lipids. Triglyceride value is given.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for one subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Panel</title>
          <description>Fasting lipids. Triglyceride value is given.</description>
          <population>All available data were used; data were not available for one subject.</population>
          <units>Change in triglyceride, mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" lower_limit="-68" upper_limit="8"/>
                    <measurement group_id="O2" value="-10" lower_limit="-33" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Intimal Medial Thickness (cIMT)</title>
        <description>Carotid Intimal Medial Thickness (cIMT).</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Intimal Medial Thickness (cIMT)</title>
          <description>Carotid Intimal Medial Thickness (cIMT).</description>
          <population>All available data were used.</population>
          <units>Change in mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.07" upper_limit="-0.00"/>
                    <measurement group_id="O2" value="-0.00" lower_limit="-0.03" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tolerance</title>
        <description>Glucose tolerance as measured by standard oral glucose tolerance test. 2-hour glucose is given.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used; data were not available for some subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance</title>
          <description>Glucose tolerance as measured by standard oral glucose tolerance test. 2-hour glucose is given.</description>
          <population>All available data were used; data were not available for some subjects.</population>
          <units>Change in 2-hour glucose, mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-18" upper_limit="15"/>
                    <measurement group_id="O2" value="-8" lower_limit="-24" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin</title>
        <description>adiponectin.</description>
        <time_frame>6 months</time_frame>
        <population>All available data were used. Data were not available for 1 subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin</title>
          <description>adiponectin.</description>
          <population>All available data were used. Data were not available for 1 subject.</population>
          <units>Change in ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-515" upper_limit="1159"/>
                    <measurement group_id="O2" value="0" lower_limit="-1030" upper_limit="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemostatic Markers</title>
        <description>Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) measured in serum.</description>
        <time_frame>6 months</time_frame>
        <population>Please note that we do not have data for these markers (neither PAI1 or tPA) because we did not have adequate funds to assess these.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin</title>
            <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Inactive Injection)</title>
            <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostatic Markers</title>
          <description>Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) measured in serum.</description>
          <population>Please note that we do not have data for these markers (neither PAI1 or tPA) because we did not have adequate funds to assess these.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month randomized portion of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tesamorelin</title>
          <description>Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Inactive Injection)</title>
          <description>Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <description>exacerbation of existing congestive heart failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>esophageal myotomy</sub_title>
                <description>Planned Heller myotomy requiring post-procedure hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>pneumonia requiring hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>basal cell carcinoma</sub_title>
                <description>diagnoses of basal cell carcinoma in 2 patients, both of whom had history of basal cell carcinoma in past</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <description>acute cerebrovascular accident</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <description>arthralgia</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>muscle pain</sub_title>
                <description>myalgia</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>erythema at injection site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>stinging of skin</sub_title>
                <description>stinging at injection site</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Please note that we intended to collect and analyze data on PAI1 and tPA but we did not have sufficient funds to do this.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven K. Grinspoon, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

